Nonalcoholic Fatty Liver Disease Clinical Trial
Official title:
Effects of Compound Silymarin on Biomarkers of Lipid Metabolism and Inflammation in Patients With Non-alcoholic Fatty Liver Disease: A Randomized Controlled Double-blind Trial
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China. The aim of this project is to evaluate the effects of compound silymarin on biomarkers of lipid metabolism and inflammation in the patients with NAFLD.
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but still has no exact therapy for this disease instead of improving our diet and enhancing physical activity. Silymarin is a mixture of flavonoids extracted from seeds of Silybum marianum or milk thistle, and its major active compound is silibinin. Because of its antioxidant, anti-inflammatory and antifibrotic power, silymarin has important biological effects in NAFLD. Furthermore, some traditional liver protective Chinese medicines are also helpful in controlling the progression of NAFLD, such as pueraria, schisandra and salvia miltiorrhiza. At present, there are few reports on the combination of silymarin and these traditional Chinese medicines in the treatment of NAFLD. This study aims to test the effect of compound silymarin on laboratory markers and clinical evolution of patients with NAFLD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06138327 -
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
|
Phase 1 | |
| Completed |
NCT01045499 -
LAGB as a Treatment for Morbid Obesity in Adolescents
|
N/A | |
| Completed |
NCT03674476 -
An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function
|
Phase 1 | |
| Not yet recruiting |
NCT05495139 -
Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease
|
N/A | |
| Completed |
NCT04988204 -
Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
|
N/A | |
| Recruiting |
NCT04369521 -
Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease
|
N/A | |
| Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 | |
| Enrolling by invitation |
NCT00983463 -
Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
|
||
| Recruiting |
NCT00658164 -
Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores
|
Phase 3 | |
| Recruiting |
NCT02148471 -
Fatty Acids, Genes and Microbiota in Fatty Liver
|
N/A | |
| Completed |
NCT03656744 -
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
|
Phase 2 | |
| Not yet recruiting |
NCT01735799 -
THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS
|
N/A | |
| Completed |
NCT01446276 -
Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease
|
N/A | |
| Completed |
NCT00930384 -
A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
|
N/A | |
| Recruiting |
NCT02469272 -
Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study
|
Phase 1 | |
| Completed |
NCT02132780 -
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
|
N/A | |
| Terminated |
NCT01355575 -
Rifaximin in Fatty Liver Disease
|
Phase 4 | |
| Completed |
NCT01399645 -
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
|
Phase 2 | |
| Completed |
NCT01210989 -
Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
|
N/A | |
| Completed |
NCT03434613 -
Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease
|
Phase 4 |